TY - JOUR
T1 - Widespread alterations in systemic immune profile are linked to lung function heterogeneity and airway microbes in cystic fibrosis
AU - Rossi, Elio
AU - Lausen, Mads
AU - Øbro, Nina Friesgaard
AU - Colque, Antonella
AU - Nielsen, Bibi Uhre
AU - Møller, Rikke
AU - de Gier, Camilla
AU - Hald, Annemette
AU - Skov, Marianne
AU - Pressler, Tacjana
AU - Ostrowski, Sisse Rye
AU - Marquart, Hanne Vibeke
AU - Johansen, Helle Krogh
N1 - Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2024/9
Y1 - 2024/9
N2 - BACKGROUND: Excessive inflammation and recurrent airway infections characterize people with cystic fibrosis (pwCF), a disease with highly heterogeneous clinical outcomes. How the overall immune response is affected in pwCF, its relationships with the lung microbiome, and the source of clinical heterogeneity have not been fully elucidated.METHODS: Peripheral blood and sputum samples were collected from 28 pwCF and an age-matched control group. Systemic immune cell subsets and surface markers were quantified using multiparameter flow cytometry. Lung microbiome composition was reconstructed using metatranscriptomics on sputum samples, and microbial taxa were correlated to circulating immune cells and surface markers expression.RESULTS: In pwCF, we found a specific systemic immune profile characterized by widespread hyperactivation and altered frequencies of several subsets. These included substantial changes in B-cell subsets, enrichment of CD35+/CD49d+ neutrophils, and reduction in dendritic cells. Activation markers and checkpoint molecule expression levels differed from healthy subjects. CTLA-4 expression was increased in Tregs and, together with impaired B-cell subsets, correlated with patients' lung function. Concentrations and frequencies of key immune cells and marker expression correlated with the relative abundance of commensal and pathogenic bacteria in the lungs.CONCLUSION: The CF-specific immune signature, involving hyperactivation, immune dysregulation with alteration in Treg homeostasis, and impaired B-cell function, is a potential source of lung function heterogeneity. The activity of specific microbes contributes to disrupting the balance of the immune response. Our data provide a unique foundation for identifying novel markers and immunomodulatory targets to develop the future of cystic fibrosis treatment and management.
AB - BACKGROUND: Excessive inflammation and recurrent airway infections characterize people with cystic fibrosis (pwCF), a disease with highly heterogeneous clinical outcomes. How the overall immune response is affected in pwCF, its relationships with the lung microbiome, and the source of clinical heterogeneity have not been fully elucidated.METHODS: Peripheral blood and sputum samples were collected from 28 pwCF and an age-matched control group. Systemic immune cell subsets and surface markers were quantified using multiparameter flow cytometry. Lung microbiome composition was reconstructed using metatranscriptomics on sputum samples, and microbial taxa were correlated to circulating immune cells and surface markers expression.RESULTS: In pwCF, we found a specific systemic immune profile characterized by widespread hyperactivation and altered frequencies of several subsets. These included substantial changes in B-cell subsets, enrichment of CD35+/CD49d+ neutrophils, and reduction in dendritic cells. Activation markers and checkpoint molecule expression levels differed from healthy subjects. CTLA-4 expression was increased in Tregs and, together with impaired B-cell subsets, correlated with patients' lung function. Concentrations and frequencies of key immune cells and marker expression correlated with the relative abundance of commensal and pathogenic bacteria in the lungs.CONCLUSION: The CF-specific immune signature, involving hyperactivation, immune dysregulation with alteration in Treg homeostasis, and impaired B-cell function, is a potential source of lung function heterogeneity. The activity of specific microbes contributes to disrupting the balance of the immune response. Our data provide a unique foundation for identifying novel markers and immunomodulatory targets to develop the future of cystic fibrosis treatment and management.
KW - Adult
KW - Cystic Fibrosis/microbiology
KW - Female
KW - Flow Cytometry
KW - Humans
KW - Lung/immunology
KW - Male
KW - Microbiota/immunology
KW - Respiratory Function Tests/methods
KW - Sputum/microbiology
UR - http://www.scopus.com/inward/record.url?scp=85191943896&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2024.04.015
DO - 10.1016/j.jcf.2024.04.015
M3 - Journal article
C2 - 38702223
SN - 1569-1993
VL - 23
SP - 885
EP - 895
JO - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
JF - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
IS - 5
ER -